Drug Type Small molecule drug |
Synonyms CX-510 |
Target |
Action antagonists |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-Small Cell Lung Cancer | Phase 1 | China | - | |
| Non-Small Cell Lung Cancer | Phase 1 | China | - | |
| Solid tumor | IND Approval | China | 05 Mar 2022 |





